| Market value | 10.65M |
| Price to earnings (P/E) | Not meaningful (loss) |
| Price to sales | 2.4 |
| Price to book | 4.0 |
| Revenue | 4.45M |
| Net income | -3.77M |
| Gross margin | 8.1% |
| Operating margin | -119.5% |
| Net margin | -84.8% |
| Return on equity | -143.5% |
| Return on assets | -55.9% |
| Revenue growth | -16.2% |
| Cash and equivalents | 1.31M |
| Current ratio | 1.62 |
| EPS, diluted (last 12 months) | -1.27 |
| Shares outstanding | 4.59M |
| Dividends paid (last 12 months) | None |
| Price | 2.32 |
| 52-week high | 3.21 |
| 52-week low | 1.45 |
| 1-year price change | -18.60% |
| Average volume (3 months) | 71.1K |
| Beta against the S&P 500 (1 year) | 0.79 |
Calculated from Biomerica Inc.'s SEC filings (latest quarter ending May 31, 2026) and the price above. "Last 12 months" adds up the four most recent quarters. Beta compares one year of daily returns with the S&P 500 (SPY). Dividends from Polygon.io or Nasdaq.